Atrium Therapeutics kompaniyasidagi eng so‘nggi ish o‘rinlari

Atrium Therapeutics is a clinical-stage biotechnology company developing RNA medicines for genetic and rare heart diseases. Its cardiac delivery platform builds on antibody-oligonucleotide conjugate technology to direct oligonucleotide therapies to heart muscle. The pipeline includes ATR-1072 for PRKAG2 syndrome and ATR-1086 for PLN cardiomyopathy, alongside research-stage programs for other rare cardiomyopathies. Atrium plans to file an investigational new drug application for ATR-1072 in the second half of 2026. The company’s work brings together RNA therapeutics and precision cardiology, with its research and development programs focused on conditions affecting the heart.